Evidence map›Paper›PMID 25100831›Full record

ArticleJournal of virology2014

Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.

Hailong Guo, Steven F Baker, Luis Martínez-Sobrido, David J Topham

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Triphasic production of IFNDiscovery immunology · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Tissue-resident CD8Science immunology · 2020
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Influenza A Virus Studies in a Mouse Model of Infection.Journal of visualized experiments : JoVE · 2017
    Article
  17. Article
  18. Article
  19. Reverse Genetics Approaches for the Development of Influenza Vaccines.International journal of molecular sciences · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hailong GuoCenter for Infectious Diseases and Vaccine Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA jackguo1234@yahoo.com david_topham@urmc.rochester.edu.
Steven F BakerDepartment of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
Luis Martínez-SobridoDepartment of Microbiology and Immunology, University of Rochester, Rochester, New York, USA.
David J TophamDavid H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, University of Rochester, Rochester, New York, USA jackguo1234@yahoo.com david_topham@urmc.rochester.edu.
University of Rochester · USRochester General Hospital · US

Funding

Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2012 to 2022
$17.6M
The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Anti-interferon Activity of the Arenavirus NucleoproteinR01AI077719 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI DE LA TORRE, JUAN C., MARTINEZ-SOBRIDO, LUIS · 2009 to 2012
$1.6M
Single-cycle Infectious Candid#1 to Study Hemorrhagic Fever New World ArenavirusR03AI099681 · NIAID · UNIVERSITY OF ROCHESTER · PI MARTINEZ-SOBRIDO, LUIS · 2012 to 2013
$154k
NIAID NIH HHS AI 007285-26NIAID NIH HHS HHSN266200700008CNIAID NIH HHS HHSN272201000055CNIAID NIH HHS P01 AI097092NIAID NIH HHS P01AI097092NIAID NIH HHS R01 AI077719NIAID NIH HHS R03 AI099681NIAID NIH HHS R03AI099681-01A1NIAID NIH HHS T32 AI007285
6 · The paper itself

Abstract

The effector functions of specific CD8 T cells are crucial in mediating influenza heterologous protection. However, new approaches for influenza vaccines that can trigger effective CD8 T cell responses have not been extensively explored. We report here the generation of single-cycle infectious influenza virus that lacks a functional hemagglutinin (HA) gene on an X31 genetic background and demonstrate its potential for triggering protective CD8 T cell immunity against heterologous influenza virus challenge. In vitro, X31-sciIV can infect MDCK cells, but infectious virions are not produced unless HA is transcomplemented. In vivo, intranasal immunization with X31-sciIV does not cause any clinical symptoms in mice but generates influenza-specific CD8 T cells in lymphoid (mediastinal lymph nodes and spleen) and nonlymphoid tissues, including lung and bronchoalveolar lavage fluid, as measured by H2-Db NP366 and PA224 tetramer staining. In addition, a significant proportion of X31-sciIV-induced antigen-specific respiratory CD8 T cells expressed VLA-1, a marker that is associated with heterologous influenza protection. Further, these influenza-specific CD8 T cells produce antiviral cytokines when stimulated with NP366 and PA224 peptides, indicating that CD8 T cells triggered by X31-sciIV are functional. When challenged with a lethal dose of heterologous PR8 virus, X31-sciIV-primed mice were fully protected from death. However, when CD8 T cells were depleted after priming or before priming, mice could not effectively control virus replication or survive the lethal challenge, indicating that X31-sciIV-induced memory CD8 T cells mediate the heterologous protection. Thus, our results demonstrate the potential for sciIV as a CD8 T cell-inducing vaccine. Importance: One of the challenges for influenza prevention is the existence of multiple influenza virus subtypes and variants and the fact that new strains can emerge yearly. Numerous studies have indicated that the effector functions of specific CD8 T cells are crucial in mediating influenza heterologous protection. However, influenza vaccines that can trigger effective CD8 T cell responses for heterologous protection have not been developed. We report here the generation of an X31 (H3N2) virus-derived single-cycle infectious influenza virus, X31-sciIV. A one-dose immunization with X31-sciIV is capable of inducing functional influenza virus-specific CD8 T cells that can be recruited into respiratory tissues and provide protection against lethal heterologous challenge. Without these cells, protection against lethal challenge was essentially lost. Our data indicate that an influenza vaccine that primarily relies on CD8 T cells for protection could be developed.

Indexed as

AnimalsCD8-Positive T-LymphocytesDogsDose-Response Relationship, ImmunologicEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHEK293 CellsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeLymphocyte DepletionMiceMice, Inbred C57BLHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID25100831
PMCPMC4178714
OpenAlexW2119257220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.